전체메뉴 ALL MENU

[경력사항]
2016.3. - 2017.2. 서울아산병원 인턴
2017.3. - 2020.2. 서울아산병원 내과 전공의
2020.3. - 2022.2. 서울아산병원 내분비내과 전임의
2022.3. - 2023.2. 서울아산병원 내분비내과 진료전임강사
2023.3. - 2024.8. 단국대학교 내분비대사내과 임상조교수
2024. 9. - 현재) 단국대학교 의과대학 내분비대사내과 조교수


[상훈]
2020. 10. 31 대한내분비학회 Plenary Oral Presentation
2021. 04. 10 대한내분비학회 최우수연제상
2022. 08. 20 대한갑상선학회 국제학회논문상
2022. 08. 20 대한갑상선학회 우수연제상
2022. 10. 28 대한내분비학회 Best Poster Oral Presentation

[학회활동]
대한내과학회 정회원
대한내분비학회 평생회원
대한갑상선학회 평생회원
대한당뇨병학회 정회원

1. A Case of Severe Pneumocystitis Pneumonia in a Thyroid Cancer Patient Receiving Lenvatinib. 2019, International Journal of Thyroidology 12:127-131.

2. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy. 2020, Endocrinol Metab (Seoul) 35:602-609.

3. Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study. 2020, Endocrinol Metab (Seoul) 35:618-627.

4. Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis. 2020, Endocrinol Metab (Seoul) 35:830-837.

5. Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas. 2021, Cancers (Basel) 13.

6. Anaplastic Thyroid Carcinoma with Initial Ultrasonography Features Mimicking Subacute Thyroiditis. 2021, Endocrinol Metab (Seoul) 36:201-202.

7. SHMT2 expression as a diagnostic and prognostic marker for thyroid cancer. 2021, Endocr Connect 10:630-636.

8. Clinical implications of age and excellent response to therapy in patients with high-risk differentiated thyroid carcinoma. 2021, Clin Endocrinol (Oxf) 95:882-890.

9. Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Microcarcinoma: A Multicenter Cohort Study in Korea. 2021, Thyroid 31:1494-1501.

10. Clinicopathological Characteristics and Disease-Free Survival in Patients with Hurthle Cell Carcinoma: A Multicenter Cohort Study in South Korea. 2021, Endocrinol Metab (Seoul) 36:1078-1085.

11. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry. 2021, Thyroid 31:61-67.

12. Death-Associated Protein Kinase 1 Inhibits Progression of Thyroid Cancer by Regulating Stem Cell Markers. 2021, Cells 10.

13. Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAF(V600E)-Mutant Advanced Papillary Thyroid Carcinoma. 2021, Cancers (Basel) 13.

14. Clinical Characteristics and Prognosis of Coexisting Thyroid Cancer in Patients with Graves Disease: A Retrospective Multicenter Study. 2021, Endocrinol Metab (Seoul) 36:1268-1276.

15. Comparison of 99mTc Pertechnetate Thyroid Uptake Rates by Gamma Probe and Gamma Camera Methods for Differentiating Graves’ Disease and Thyroiditis. 2022, Nuclear Medicine and Molecular Imaging 56:42-51.

16. Graves disease diagnosed in remnant thyroid after lobectomy for thyroid cancer. 2022, PLoS One 17:e0265332.

17. Effect of TSH levels during active surveillance of PTMC according to age. 2022, Endocr Relat Cancer 29:191-200.

18. Immunoglobulin G4-Related Thyroid Disease: A Single-Center Experience and Literature Review. 2022, Endocrinol Metab (Seoul) 37:312-322.

19. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study. 2022, Thyroid. doi: 10.1089/thy.2022.0054.

20. Limitations of fine-needle aspiration and core needle biopsies in the diagnosis of tall cell variant of papillary thyroid carcinoma. 2022, Clin Endocrinol (Oxf). doi: 10.1111/cen.14735.

21. Prognosis of Patients with 1-4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles. 2022, Ann Surg Oncol. doi: 10.1245/s10434-022-12155-2.

22. Serum thyroglobulin testing after thyroid lobectomy in patients with 1-4？cm papillary thyroid carcinoma. Endocrine. 2023;81(2):290-7.

23. Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib. Endocrine. 2023;81(2):298-305

24. Long-term follow-up result of antithyroid drug treatment of Graves hyperthyroidism in a large cohort. Eur Thyroid J.2023;12(2)

25. Changes in peripheral blood immune cell population in thyroid cancer patients treated with lenvatinib. Sci Rep.2023;12 (1):12765

26. Acute thyrotoxicosis following a horse-induced neck trauma. 2024, International Journal of Thyroidology 17 (1): 245-249

27. Prognostic roles of inflammatory biomarkers in radioiodine-refractory thyroid cancer treated with lenvatinib. 2024, Endocrinol Metab (Seoul) 39 (2): 334-343

28. Dynamic risk model for the medical treatment of Graves’ hyperthyroidism according to treatment duration. 2024, Endocrinol Metab (Seoul) 39 (4): 579-589